Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse-free survival. Methods: Forty patients who received docetaxel and epirubicinas neoadjuvant chemotherapy for locally advanced breast cancer were evaluated retrospectively. Neoadjuvant chemotherapy consisted of intravenous injection of 75 mg/m2 docetaxel and 60 mg/m2 epirubucin on day 1, every 21 days, and two to six cycles. Results: Twenty-five (62.5%) patients showed a partial response, and 15 (37.5%) patients showed a stable disease in the first response evaluation after two or three cycles of neoadjuvant chemotherapy. In the second response evaluation of nine patients who received six cycles of neoadjuvant chemotherapy, one patient achieved a complete response, but two patients with hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer experienced disease progression. Twenty-five (62.5%) patients experienced downstaging after neoadjuvant chemotherapy. Patients with > 20% pretreatment Ki-67 and decrease of Ki-67 between pre- and post-neoadjuvant chemotherapy showed a trend for better response. In multivariate analysis, advanced pathological stage showed a significant negative effect on relapse-free survival. Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki- 67 may play a role as predictive factor for response to neoadjuvant chemotherapy.
Abstract
Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse-free survival. Methods: Forty patients who received docetaxel and epirubicinas neoadjuvant chemotherapy for locally advanced breast cancer were evaluated retrospectively. Neoadjuvant chemotherapy consisted of intravenous injection of 75 mg/m2 docetaxel and 60 mg/m2 epirubucin on day 1, every 21 days, and two to six cycles. Results: Twenty-five (62.5%) patients showed a partial response, and 15 (37.5%) patients showed a stable disease in the first response evaluation after two or three cycles of neoadjuvant chemotherapy. In the second response evaluation of nine patients who received six cycles of neoadjuvant chemotherapy, one patient achieved a complete response, but two patients with hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer experienced disease progression. Twenty-five (62.5%) patients experienced downstaging after neoadjuvant chemotherapy. Patients with > 20% pretreatment Ki-67 and decrease of Ki-67 between pre- and post-neoadjuvant chemotherapy showed a trend for better response. In multivariate analysis, advanced pathological stage showed a significant negative effect on relapse-free survival. Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki- 67 may play a role as predictive factor for response to neoadjuvant chemotherapy.
참고문헌 (20)
- Thompson AM, "Neoadjuvant treatment of breast cancer", Ann Oncol, 23, pp.x231~x236 (2012)
- Early Breast Cancer Trialists’ Collaborative Group, "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- Mamounas EP, "Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28", J Clin Oncol, 23, pp.3686~3696 (2005)
- Henderson IC, "Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer", J Clin Oncol, 21, pp.976~983 (2003)
- Wolmark N, "Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18", J Natl Cancer Inst Monogr, pp.96~102 (2001)
- Bear HD, "Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27", J Clin Oncol, 24, pp.2019~2027 (2006)
- Sessa C, "Docetaxel and epirubicin in advanced breast cancer", Oncologist, 6, pp.13~16 (2001)
- Hirano A, "The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer", Anticancer Res, 26, pp.581~584 (2006)
- Papadimitriou K, "Neoadjuvant therapy for locally advanced breast cancer : focus on chemotherapy and biological targeted treatments’ armamentarium", J Thorac Dis, 2, pp.160~170 (2010)
- Gianni L, "Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort", Lancet, 375, pp.377~384 (2010)
- Palmieri C, "Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer", Oncotarget, 7, pp.13209~13220 (2016)
- Gianni L, "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial", Lancet Oncol, 13, pp.25~32 (2012)
- Hurvitz SA, "Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial", Lancet Oncol, 19, pp.115~126 (2018)
- Faneyte IF, "Breast cancer response to neoadjuvant chemotherapy : predictive markers and relation with outcome", Br J Cancer, 88, pp.406~412 (2003)
- Gillon P, "Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994", BIG 1-00 study, 2017, pp.79, 226~234
- Li X, "Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery : a systematic review and meta-analysis", World J Surg Oncol, 15, pp.210~ (2017)
- von Minckwitz G, "Ki67 measured after neoadjuvant chemotherapy for primary breast cancer", Clin Cancer Res, 19, pp.4521~4531 (2013)
- Nishimura R, "Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis", Breast Cancer, 17, pp.269~275 (2010)
- Dowsett M, "Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer", J Natl Cancer Inst, 99, pp.167~170 (2007)
- Tao M, "Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis", Medicine(Baltimore), 96, pp.e9384~ (2017)